Skip to content
Screener

Design Therapeutics, Inc. DSGN Q1 2026 earnings

Reported April 28, 2026 · Before market open

Revenue-
EPS-$0.29Beat by $0.07
EPS estimate-$0.36

Next report

Nov 4, 2026 (in 2 months)
EPS estimate-$0.38

Financials

Q1 2026

Income statement

See full
Revenue-—
Operating income-$19.7M+3.5%
Net income-$17.6M+0.4%
EPS (diluted)-$0.29+6.5%

Balance sheet

See full
Cash & equivalents$12.8M-6.6%
Total debt$2.7M+27.7%
Total equity$218.1M-4.3%
Total assets$230.4M-3.0%

Cash flow

See full
Operating cash flow-$16.4M+2.1%
CapEx--100%
Free cash flow-$16.4M+2.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$656.19M+199%
Enterprise value$646.16M+211%

Returns & leverage

See full
Return on equity-31.3%+19.5pp
Debt / equity0×0.0×
Current ratio22.3×-6.1×

FAQ

When did Design Therapeutics, Inc. report Q1 2026 earnings?
Design Therapeutics, Inc. (DSGN) reported Q1 2026 earnings on April 28, 2026 before market open.
What were Design Therapeutics, Inc.'s Q1 2026 revenue and EPS?
Design Therapeutics, Inc. reported revenue of - and eps of $-0.29 for Q1 2026.
Did Design Therapeutics, Inc. beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.36 by $0.07.
How did Design Therapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 6.5% from $-0.31.
Where can I find Design Therapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-187012) and the 10-Q periodic report (0001193125-26-187063) directly on SEC EDGAR. The filing index links above go to sec.gov.